Krebsimpfungen: Der Jackpot ist noch nicht geknackt
Vielversprechende Studiendaten der Pharmafirmen Moderna und Merck lassen Patienten und Investoren hoffen. Für eine breite Anwendung der Technologie gibt es allerdings noch Hürden.
In a recent clinical study, pharmaceutical companies Moderna and Merck have shown promising results, potentially leading to the development of a cancer vaccine. The news has generated optimism, as evidenced by a significant increase in Moderna's stock price on Wednesday, with a 177% jump. The trial involved patients receiving Moderna's vaccine in combination with Merck's cancer medication, Keytruda.
This therapy is not a traditional vaccine, as it aims to enhance the patient's immune system to target and destroy existing cancer cells, rather than preventing the disease altogether. The study involved over 1,100 patients and demonstrated that the combined treatment significantly reduced the risk of tumor recurrence within five years after surgery compared to the control group.
However, it is unclear whether the combination therapy extends patients' overall survival. Experts eagerly await the detailed results, which could mark a breakthrough in using mRNA tumor vaccines. Personalization of the vaccine is crucial, as cancer molecules vary significantly among patients. The vaccine is tailored by identifying specific mutated molecules on the cancer cells, allowing the immune system to recognize and attack these cells.
Despite the potential benefits, the personalized treatment is expensive and time-consuming, with the current production process taking about six weeks.
Written by urgent.news from NZZ Wirtschaft's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
